H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer

<table class="table-group" id="tab1"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td align="left">Treatment</td><td align="center">No metastases</td><td align="center">Few metastases (&lt;4)</td><td align="center">Numerous metastases (&gt;4)</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td align="left">BC-819 + gemcitabine</td><td align="center">100%</td><td align="center"></td><td align="center"></td></tr><tr><td align="left">Gemcitabine</td><td align="center">37%</td><td align="center">63%</td><td align="center"></td></tr><tr><td align="left">No treatment</td><td align="center"></td><td align="center"></td><td align="center">100%</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Metastases observation developed in the hamster orthotopic pancreatic carcinoma model. Abdominal cavity was searched for metastases in the animals groups described in Figures <a href="../fig1/#a">1(a)</a> and <a href="../fig1/#b">1(b)</a>. 

International Scholarly Research Notices

tab1

Table 1

Table 1: H19-Promoter-Targeted Therapy Combined with Gemcitabine in the Treatment of Pancreatic Cancer 